Ranibizumab Vs Bevacizumab for Type 1 Retinopathy of Prematurity
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
Retinopathy of prematurity (ROP) with inadequate growth and development of retinal blood
vessels in premature infants is one of the foremost reasons for childhood blindness. Recently
there is a shift of treatment to VEGF inhibitors which can regress ROP without destroying the
peripheral retina. Yet, the best drug has not been identified.Bevacizumab is a larger,
full-length immunoglobulin G (IgG) molecule with slower retinal clearance and therefore
prolonged diffusion into the systemic circulation, up to 3 weeks. In contrast, the systemic
half-life of a Fab molecule, such as ranibizumab, is a few hours. The objective is to compare
the efficacy and reliability of intravitreal bevacizumab with standard 0.625 mg dose and
intravitreal ranibizumab treatments for type 1 ROP, namely pattern of disease regression,
recurrence of ROP, necessity of subsequent ablative procedures.